Daiichi Sankyo Advances Science and Technology to Transform Lives

Dear Stakeholders,

For more than 125 years, Daiichi Sankyo has been driven by a simple but powerful question: what else can we do for patients? That question continues to define our purpose as we enter a new era of growth and possibility.

We are proud to share our 2035 Vision: to be a trusted healthcare innovator transforming the lives of people through our science and technology. This vision reflects who we are, what we believe, and where we are going.

Our new Five-Year Business Plan, covering FY2026 through FY2030, is designed to accelerate our progress toward this vision. We aim to deliver more than 20 new indications across five medicines and establish ourselves as a global top five oncology company by 2035. These ambitions are bold, but they are grounded in our strengths and in our unwavering commitment to patients.

At the center of our strategy are the breakthroughs created by Daiichi Sankyo. Our industry-leading antibody drug conjugate platform continues to expand what is possible in oncology, while our focus on new breakthrough generating technologies will help us bring new medicines forward faster and with greater precision.

We place great importance on the philosophy of Sanpo Yoshi — creating value that is good for the seller, the buyer, and for society. Lasting success must be shared with patients, healthcare professionals, employees, shareholders, and the communities we serve. We are committed to advancing not only better health outcomes, but also a more sustainable future through responsible business practices, environmental stewardship, and strong governance. By reducing our environmental footprint, improving operational efficiency, and working with partners who share our values, we aim to contribute to a healthier society for generations to come.

We believe progress begins with the courage to ask the right questions. We challenge assumptions, build on what we learn, and turn science into treatments that can make a meaningful difference in people’s lives. Behind every innovation is a person — a patient, a family, a future — and it is their lives that give our work its deepest purpose.

This progress is made possible by our people. Across Daiichi Sankyo, our culture is rooted in scientific rigor, sustained by perseverance, and committed to excellence. Our scientists are empowered to explore, challenge, and contribute freely. Across the organization, every team member plays a vital role in moving science forward and delivering our innovation to patients around the world.

As we look ahead, we remain guided by our enduring belief in asking more of science to transform lives, pioneer treatments for unmet medical needs, and expand access to more people who are waiting for better answers.

We sincerely thank our patients, healthcare professionals, employees, shareholders, and the communities for their continued trust and support. Together, we will shape what comes next in oncology and beyond.

Hiroyuki Okuzawa 
Representative Director
President and CEO